



October 30, 2015

To whom it may concern:

VITAL KSK HOLDINGS, INC.

Representative: Mr. Taisuke Murai, President & CEO

(Code number: 3151, Tokyo Stock Exchange, First Section)

Contact: Mr. Masaaki Tsugoshi, Director and General Manager,

Business Planning and General Affairs

(Tel. +81-3-3275-3303)

Notice of Revision of Earnings Forecast

In light of recent earnings trends and other factors, VITAL KSK HOLDINGS, INC. (hereinafter the “Company”) hereby announces a revision of its earnings forecast released on May 14, 2015, as follows.

1. Revision of consolidated earnings forecast for the first half of the fiscal year ending March 31, 2016

(April 1, 2015 to September 30, 2015)

| | Net sales | Operating income | Ordinary income | Net income attributable to owners of parent | Net income per share |
|---|------------------------|--------------------|----------------------|---|----------------------|
| Previously announced forecast (A) | Million yen 281,000 | Million yen 430 | Million yen 2,200 | Million yen 1,400 | Yen 25.04 |
| Revised forecast (B) | 286,750 | 990 | 2,850 | 1,930 | 34.52 |
| Difference (B-A) | 5,750 | 560 | 650 | 530 | |
| Increase/decrease (%) | 2.0 | 130.2 | 29.5 | 37.9 | |
| (Reference) Results for the first half of the previous fiscal year (ended March 31, 2015) | 265,486 | 756 | 3,233 | 2,536 | 43.76 |

2. Revision of consolidated earnings forecast for the fiscal year ending March 31, 2016

(April 1, 2015 to March 31, 2016)

| | Net sales | Operating income | Ordinary income | Net income attributable to owners of parent | Net income per share |
|--|------------------------|----------------------|----------------------|---|----------------------|
| Previously announced forecast (A) | Million yen 573,600 | Million yen 1,850 | Million yen 5,340 | Million yen 3,420 | Yen 61.16 |
| Revised forecast (B) | 600,000 | 3,000 | 6,500 | 4,200 | 75.11 |
| Difference (B-A) | 26,400 | 1,150 | 1,160 | 780 | |
| Increase/decrease (%) | 4.6 | 62.2 | 21.7 | 22.8 | |
| (Reference) Results for the previous fiscal year (ended March 31, 2015) | 548,012 | 1,812 | 6,125 | 4,527 | 79.51 |

3. Reasons for the revision

Net sales, operating income, ordinary income and net income attributable to owners of parent for the first half are expected to surpass earlier forecasts, due to sales of hepatitis C medications that were significantly higher than forecast, combined with the effects of cost-cutting measures. Likewise, net sales, operating income, ordinary income and net income attributable owners of parent have also been revised for the full fiscal year as shown above, as hepatitis C medication sales are expected to remain strong through the third quarter and beyond.

Note: The above earnings forecasts are compiled based on materials available at the time of announcement. Actual results may differ from forecasts due to various factors.